GW Pharmaceuticals (GW Pharmaceuticals) Total Current Assets : $718.7 Mil (As of Mar. 2021)

View and export this data going back to . Start your Free Trial

What is GW Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. GW Pharmaceuticals's total current assets for the quarter that ended in Mar. 2021 was $718.7 Mil.

GW Pharmaceuticals Total Current Assets Historical Data

The historical data trend for GW Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GW Pharmaceuticals Total Current Assets Chart

GW Pharmaceuticals Annual Data

Trend

Sep11

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Dec19

Dec20

Total Current Assets

Get a 7-Day Free Trial

527.09

364.58

390.71

699.64

729.53

GW Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Total Current Assets	Get a 7-Day Free Trial															672.75	687.72	720.28	729.53	718.73

GW Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

GW Pharmaceuticals's Total Current Assets for the fiscal year that ended in Dec. 2020 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	486.752	+	71.168	+	129.138	+	42.472
	=	729.5

GW Pharmaceuticals's Total Current Assets for the quarter that ended in Mar. 2021 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	458.101	+	84.947	+	137.627	+	38.058
	=	718.7

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

GW Pharmaceuticals (OTCPK:GWPRF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

GW Pharmaceuticals's Liquidation Value for the quarter that ended in Mar. 2021 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	458.101	-	197.97	+	0.75 * 84.947	+	0.5 * 137.627
=	392.7

GW Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (OTCPK:GWPRF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ

Website

http://www.gwpharm.com

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.